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Abstract 
Background: Recording of motor evoked potentials (MEPs) is used during navigated transcranial magnetic stimula-
tion (nTMS) motor mapping to locate motor function in the human brain. However, factors potentially underlying 
MEP latency variability in neurosurgical motor mapping are vastly unknown. In the context of this study, one hun-
dred brain tumor patients underwent preoperative nTMS-based motor mapping of the tumor hemisphere between 
2010 and 2013. Fourteen predefined predictor variables were recorded, and MEP latencies of abductor pollicis brevis 
muscle (APB), abductor digiti minimi muscle (ADM), and flexor carpi radialis muscle (FCR) were analyzed using linear 
mixed-effect multiple regression analysis with the forward step-wise model comparison approach.
Results: Common factors (relevant to APB, ADM, and FCR) for MEP latency variability were gender, most likely due 
to body height, and antiepileptic drug (AED) intake. Muscle-specific factors (relevant to APB, ADM, or FCR) for MEP 
latency variability were resting motor threshold (rMT), tumor side, and tumor location.
Conclusions: Based on a large cohort of neurosurgical patients, this study provides data on a wide range of clinical 
factors that may underlie MEP latency variability. The factors that significantly contributed to MEP latency variability 
should be standardly recorded and taken into consideration during neurosurgical motor mapping.
Keywords: Brain tumor, Cortical mapping, Electromyography, Motor evoked potentials, Navigated transcranial 
magnetic stimulation, Presurgical motor mapping
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Background
Transcranial magnetic stimulation (TMS) is a noninva-
sive tool that can be applied to systematically map the 
human cortex with the aim of localizing specific function. 
Thanks to the combination of precise navigation systems 
and TMS, navigated TMS (nTMS) becomes possible, 
which can be used for reliable cortical motor mapping in 
the context of presurgical planning among patients with 
brain tumors [1–3]. In this context, it has already been 
shown that nTMS-based motor maps correlate well with 
intraoperative direct cortical stimulation (DCS) mapping, 
especially when compared to other common preop-
erative mapping modalities such as functional magnetic 
resonance imaging (fMRI) or magnetoencephalography 
(MEG) [4–7]. Furthermore, recent data provided the first 
evidence that patients with brain tumors might benefit 
from nTMS in terms of clinical outcome and survival, 
thus potentially expanding the initial role of nTMS as a 
mere preoperative planning tool [8–10].
During neurosurgical nTMS-based motor mapping, 
the functional motor area is typically identified and spa-
tially enclosed by separating cortical areas that gave rise 
to motor evoked potentials (MEPs) during stimulation 
(motor-positive spots) from those for which no ade-
quate responses were detected (motor-negative spots). 
However, to be able to achieve accurate motor maps 
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that facilitate reliable preoperative planning, improved 
clinical outcome, and perioperative risk stratification, 
precise definitions of criteria that allow for distinguish-
ing between motor-positive and motor-negative spots 
are required. Among others, MEP amplitudes and MEP 
latencies are most commonly used for this purpose [4–6]. 
Whereas MEP latencies have principally shown to remain 
comparatively stable, MEP amplitudes vary considerably 
from stimulus to stimulus in patients with pathologies of 
the nervous system as well as in healthy subjects [11–14]. 
Although  MEP latencies are considered  more robust 
and, therefore, presumably even more reliable for sepa-
rating motor-positive from motor-negative stimulation 
points, data on normative  MEP latency values and fac-
tors underlying MEP latency variability in neurosurgical 
patients have only been provided by one study so far [14]. 
However, this study primarily revealed negative results 
in the sense that no factors except gender were identi-
fied for MEP latency variability [14]. Furthermore, the 
overall topic of MEP amplitudes, latency variability, and 
influencing factors has been primarily addressed by non-
navigated TMS studies with only a few exceptions so far 
[11, 12, 15–17]. However, non-navigated TMS does not 
allow for precise control of coil angulation, orientation, 
and localization of the stimulation with respect to indi-
vidual cortical anatomy. Yet, only slight variations in coil 
placement can already lead to different responses, which 
demonstrates the need for updated values of MEP char-
acteristics by the use of nTMS [18]. Taking these aspects 
into account, the current study addresses the following 
topics:
1. While there is some literature  available on MEP 
characteristics derived from nTMS among healthy 
subjects [13, 19], data derived  from neurosurgical 
patients are rare. Thus, the present study aims to pro-
vide further evidence on MEP latency distributions 
among patients with brain tumors.
2. Except for one study, factors that might interfere 
with MEP characteristics during neurosurgical motor 
mapping have not been assessed [14]. Thus, the pre-
sent study examines clinical factors that may underlie 
MEP variability while expanding the range of factors 
that have been taken into account previously. Most of 
these factors are specific to brain tumors and are not 
examinable in healthy cohorts.
Methods
Patients and procedures
The present study was conducted among 100 patients in 
our neurosurgical department. The same cohort has been 
investigated with a different purpose in previous studies 
[20, 21].
According to our study protocol, inclusion criteria 
included individuals above age 18, with written informed 
consent, and with brain lesions affecting motor areas 
according to anatomical magnetic resonance imaging 
(MRI). Exclusion criteria included individuals below 
18 years old, general TMS exclusion criteria (e.g., coch-
lear implant, pacemaker, deep brain stimulation elec-
trodes), and plegia.
Regarding the experimental setup, the enrolled patients 
first underwent detailed clinical examinations including 
assessment of motor strength according to a standardized 
protocol with respect to the British Medical Research 
Council (BMRC) scale. Then, cranial MRI followed by 
nTMS-based motor mapping was conducted. All nTMS 
mapping sessions were systematically analyzed to be able 
to provide data on MEP latency distributions and char-
acteristics among neurosurgical patients. Moreover, vari-
ous patient-related, tumor-related, and mapping-related 
characteristics were systematically recorded for later 
regression analysis to identify factors that may underlie 
MEP latency variability.
Cranial imaging
Among other clinical sequences, our scanning protocol 
consisted of a three-dimensional gradient echo sequence 
(TR/TE: 9/4 ms, 1 mm3 isovoxel covering the whole head, 
6  min 58  s acquisition time) with and without intrave-
nous contrast administration for navigation purposes 
during nTMS. Imaging was done on a 3 Tesla scanner by 
use of an 8-channel phased array head coil (Achieva 3T, 
Philips Medical Systems, The Netherlands B.V.).
Motor mapping
Motor mapping by nTMS was performed with the Nex-
stim eXimia NBS system, version 3.2 or 4.3 (Nexstim Oy, 
Helsinki, Finland). A biphasic figure-of-eight magnetic 
coil was used for all mappings, and an integrated infra-
red tracking system allowed for real-time navigation 
during stimulation. Motor responses were continuously 
monitored using the integrated electromyography (EMG) 
system with six channels in total. All examinations were 
conducted according to a validated stimulation protocol 
by experienced investigators [5, 10, 20–22].
During nTMS, the patients sat in an adjustable chair 
with armrests, and pregelled surface electrodes were 
placed over the abductor pollicis brevis muscle (APB), 
abductor digiti minimi muscle (ADM), flexor carpi radia-
lis muscle (FCR), biceps brachii muscle (BCS), tibialis 
anterior muscle (TA), and gastrocnemius muscle (GCN) 
contralateral to the brain lesion (Neuroline 720, Ambu, 
Ballerup, Denmark). EMG recording of each muscle 
was derived from a pair of electrodes with the first elec-
trode being placed on the respective muscle belly and 
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the second electrode being placed on a nearby bony or 
tendinous part according to the recommendations of the 
system’s manufacturer. The second electrode was always 
placed distal to the first electrode for each muscle, and 
the inter-electrode distance was in the range of few 
centimeters.
Then, the resting motor threshold (rMT) as the low-
est stimulation intensity that elicits MEPs over 50 µV in 
amplitude in at least 50% of stimulation trials in a relaxed 
muscle was determined by motor mapping of the corti-
cal representation of the APB [23]. Subsequent to rMT 
determination, motor mapping of the hemisphere with 
the brain tumor was performed. In this context, we chose 
110% rMT for mapping of upper extremity (UE) muscles, 
while the lower extremity (LE) was assessed with at least 
130% rMT according to previous reports [5, 10, 20–22]. 
Mapping was performed with a distance of less than 
1 cm between single stimulation points, and the electric 
field induced by the stimulating nTMS coil was oriented 
perpendicular to the mapped gyrus for UE mapping. 
During the whole stimulation procedure, patients were 
advised to relax, and mapping was only performed when 
preinnervation levels of all recorded muscles were clearly 
below 50  µV in amplitude, thus avoiding false-positive 
stimulation spots.
After each mapping session, post hoc analysis was done 
as described earlier [4–6, 14]. In this context, only map-
ping points with MEP amplitudes greater than  or equal 
to 50  µV were taken into account for further analysis, 
and, consequently, this criterion was used to distinguish 
between motor-positive (MEP amplitudes ≥50  µV) and 
motor-negative stimulation points (MEP amplitudes 
<50  µV). Again, this approach follows the procedures 
established during earlier investigations on motor map-
ping in patients with brain tumors [5, 10, 20–22]. Hence, 
only motor-positive stimulation spots of each patient 
were further considered during MEP latency analyses of 
the present study.
Patient data collection
To identify factors that may underlie MEP latency vari-
ability, 14 predefined predictor variables were recorded. 
These variables were collected from the medical charts or 
assessed by a standardized questionnaire subsequent to 
the mappings.
In this context, patient-related parameters contained 
gender (male = M, female = F), age at exam, antiepilep-
tic drug intake (AEDs: no AED = NA, levetiracetam = L, 
other specified AEDs = SA, AED status not known = NK, 
unspecified AEDs = UA), and presence of motor deficits 
(no deficit  =  ND, deficit  =  D). Furthermore, tumor-
related factors included tumor location (Rolandic = RO, 
frontal = FR, parietal = PA, postcentral gyrus = PoG, or 
temporal = TE), tumor side (left hemisphere = LH, right 
hemisphere = RH), dominancy of the tumor hemisphere 
(non-dominant = NDO, dominant = DO), tumor-related 
edema (no edema  =  NE, edema  =  E), tumor entity 
(astrocytoma WHO grade II  =  II, astrocytoma WHO 
grade III = III, astrocytoma WHO grade IV = IV, metas-
tasis  =  ME, other entities  =  X), tumor recurrence (no 
recurrence =  NR, recurrence =  R), and tumor volume. 
Additionally, a predefined set of mapping-related param-
eters was taken into account, which consisted of the rMT 
intensity, mapped muscles (APB, ADM, FCR), and year 
of mapping (2010–2013 = Y10, Y11, Y12, Y13). The year 
of mapping can be regarded as an important external fac-
tor related to the skills of the investigators, because lower 
MEPs might potentially arise when some coil operators 
were more experienced than others.
Statistical analysis
All statistical data analysis was performed by using R, 
version 3.1.1, in combination with the MASS package 
and the effects package [24, 25] (The R Foundation for 
Statistical Computing, Vienna, Austria).
For documentation and reporting of basic patient 
and mapping characteristics, absolute frequen-
cies, means ± standard deviation (SD), and ranges were 
calculated. Regarding MEP latency data, Shapiro–Wilk 
normality test was initially performed to assess whether 
MEP latency data were normally distributed. In case 
of non-normal data distribution, descriptive statistics 
were summarized by percentile rank scores (minimum, 
median, maximum, and quartile scores), and ex-Gauss-
ian measures were calculated and used for further MEP 
latency analyses. The ex-Gaussian distribution is a math-
ematical convolution of the normal (Gaussian) and expo-
nential distributions and has three parameters: mu and 
sigma, representing the mean and SD of the Gaussian 
distribution, and tau, representing the mean and SD of 
the exponential distribution. In this context, mu repre-
sents the mode of the normally distributed part, whereas 
sigma is the measure of dispersion in the normally dis-
tributed part.
Since previous data among neurosurgical patients have 
shown gender-dependent significant differences in MEP 
latencies [14], the initial analyses for MEP distributions 
were done separately for males and females. Further-
more, to investigate the factors underlying the variability 
in MEP latency, linear mixed-effect multiple regression 
analysis with the forward step-wise model comparison 
approach was performed. To test for statistical signifi-
cance, a Chi-squared test was applied, and p < 0.05 was 
defined as the level of significance.
For initial assessment and illustration of MEP latency 
distributions, line graphs and boxplots were generated. 
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Concerning factors that proved to significantly con-
tribute to MEP latency variability, effect plots including 




Overall, 100 patients were enrolled in the present inves-
tigation, and nTMS-based motor mapping was achieved 
successfully in all subjects. During stimulation, no 
adverse events occurred. Relevant patient details, map-
ping parameters, and the set of predefined clinical fac-
tors are displayed in Table 1. The same patient cohort has 
been investigated with a different purpose in previous 
studies [20, 21].
MEP latency distribution
According to the Shapiro–Wilk normality test, MEP 
latencies were non-normally distributed in both genders. 
Importantly, the non-normal distribution of the MEP 
latencies was not adjusted by natural logarithmic trans-
formation. The non-normally distributed MEP laten-
cies for all mapped muscles of both genders are shown 
in Table  2 and Fig.  1. Furthermore, the differences in 
MEP latency distributions are compared in Table  2 and 
Fig. 2 for all mapped muscles. For both genders, median 
MEP latency values were the highest for GCN and TA, 
followed by APB and ADM (Table  2; Fig.  2). Accord-
ingly, median MEP latencies derived from FCR and BCS 
mapping were the lowest when compared to the other 
mapped muscles (Table 2; Fig. 2).
MEP latency variability
Since MEP latencies showed non-normal distribu-
tion, they were adjusted by calculating the ex-Gaussian 
measures (mu, sigma, and tau) for each mapped muscle 
and  for each patient when the number of MEPs was at 
least three. The Shapiro–Wilk normality test confirmed 
that mu was normally distributed for FCR, BCS, TA, and 
GCN for both genders (Fig. 3). Though normal distribu-
tion was not achieved for APB or ADM, outlying scores 
decreased for these muscles. Thus, linear mixed-effect 
multiple regression analysis with the forward step-wise 
model comparison approach was suitable to investigate 
the factors underlying the variability in MEP latency.
Only motor-positive stimulation spots were taken into 
account for MEP latency analyses. In total, there were 
197 observations from APB-mapped gyri, 192 observa-
tions from ADM-mapped gyri, and 157 observations 
from FCR-mapped gyri. These numbers all exceeded the 
minimum sample size required for medium effect size 
(0.15), power (0.80), and α level (0.01) [26–30]. With this 
constraint, observations from BCS-mapped, TA-mapped, 
and GCN-mapped gyri were not further assessed to 
investigate the factors underlying the variability in MEP 
latencies because they did not have the minimum num-
ber of observations required. In this context, MEPs 
derived from mapping of LE muscles were not available 
in 66 patients due to missing responses during nTMS 
with respect to the applied stimulation protocol.
As a result of the multiple regression analysis, common 
factors (relevant to APB, ADM, and FCR) and muscle-
specific factors (relevant to APB, ADM, or FCR) were 
identified (Table  3). When the individual differences 
were partialled out by the random intercept for partici-
pants, gender and AED intake were revealed to be com-
mon factors underlying MEP latency variability (Table 3). 
Muscle-specific factors were rMT for APB (mu of the 
MEP latency was predicted to be longer for patients with 
higher rMT than for those with lower rMT), tumor side 
for ADM (mu of the MEP latency was predicted to be 
longer for patients with left-sided tumors than for those 
with right-sided tumors), and tumor location for FCR 
(mu of the MEP latency was predicted to be longer for 
patients with tumors in the central or temporal regions 
when compared to patients suffering from tumors within 
frontal regions or the PoG). The results for significant 
common and muscle-specific factors underlying the MEP 
latency variability of the considered muscles are shown in 
effect plots (Figs. 4, 5, 6).
Discussion
nTMS-based motor mapping provides multiple neuro-
physiological variables, out of which mostly MEP ampli-
tude and MEP latency are commonly used to distinguish 
between motor-positive and motor-negative spots in the 
clinical setting [4–6]. In numerous studies, MEP latency 
was shown to remain comparatively  stable within indi-
viduals, whereas MEP amplitude showed a high intra-
individual and inter-individual variability [11–14]. In 
this context, the present study identified significant fac-
tors contributing to MEP latency variability, which were 
divided into common factors (relevant to APB, ADM, 
and FCR) and muscle-specific factors (relevant to APB, 
ADM, or FCR). In the following, we discuss our results 
on MEP latency variability in patients with brain tumors 
with regards to the latest literature.
Common factors underlying MEP latency variability
Gender
In our cohort of 100 patients with brain tumors, we iden-
tified gender as a common factor underlying MEP mu 
latency variability in all analyzed muscles (APB, ADM, 
and FCR). MEP mu latency was predicted to be signifi-
cantly higher in male than in female patients (Table  3; 
Figs.  4, 5, 6). However, it is important to mention that 
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Table 1 Patient and mapping characteristics
Overview on patient and mapping characteristics by gender, including age at exam, antiepileptics (AEDs: NA  no AED, L levetiracetam, SA other specified AEDs, 
NK AED status not known, UA unspecified AEDs), and presence of motor deficits (ND no deficit, D deficit). Furthermore, tumor location (RO Rolandic, FR frontal, PA 
parietal, PoG postcentral gyrus, TE temporal), tumor side (LH left hemisphere, RH right hemisphere), dominancy of the tumor hemisphere (NDO non-dominant, DO 
dominant), tumor-related edema (NE no edema, E edema), tumor entity (II astrocytoma WHO grade II, III astrocytoma WHO grade III, IV astrocytoma WHO grade IV, 
ME metastasis, X other entities), tumor recurrence (NR no recurrence, R recurrence), and tumor volume are displayed. In addition, resting motor threshold (rMT) values 
and year of mapping (Y10 exam year 2010, Y11 exam year 2011, Y12 exam year 2012, Y13 exam year 2013) are shown. All values are presented as number of patients, 
mean ± standard deviation (SD), or ranges. Dominancy data do not add up to 100 patients since it was not assessed in five patients
Male Female All
Number of patients 57 43 100







 NA 26 27 53
 L 19 11 30
 SA 4 1 5
 NK 5 3 8
 UA 3 1 4
Motor deficit
 ND 41 31 72
 D 16 12 28
Tumor location
 RO 19 16 35
 FR 15 9 24
 PA 11 8 19
 PoG 11 6 17
 TE 1 4 5
Tumor side
 LH 23 17 40
 RH 34 26 60
Dominancy
 NDO 28 25 53
 DO 26 16 42
Edema
 NE 37 31 68
 E 20 12 32
Tumor entity
 II 8 6 14
 III 4 6 10
 IV 21 17 38
 ME 14 11 25
 X 10 3 13
Tumor recurrence
 NR 44 34 78
 R 13 9 22
Tumor volume (in cm3) 27.2 ± 5.4 (19.9–42.9) 26.1 ± 5.0 (20.3–39.9) 26.7 ± 5.2 (19.9–42.9)
rMT (in %) 31.9 ± 7.5 (20–59) 36.4 ± 10.6 (22–72) 33.8 ± 9.3 (20–72)
Year of mapping
 Y10 13 16 29
 Y11 14 6 20
 Y12 10 5 15
 Y13 20 16 36
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body height was not explicitly recorded in the present 
study, which might confound our findings.
Accordingly, studies on healthy volunteers showed 
that mean MEP latencies correlate with subjects’ gender, 
height, and age, respectively [13, 31–33]. After adjust-
ing MEP latencies to height or UE length, no significant 
differences between men and women were observed. 
Resulting from that, the gender-related differences in 
MEP latencies in our study are most likely due to height 
differences between the genders. Picht et  al. reported 
on similar findings in a cohort of brain tumor patients 
undergoing preoperative nTMS-based motor mapping: 
they observed shorter median MEP latencies in the 
tumorous hemispheres of women than in men [14]. Con-
trary to Saisanen et al., they did not report any findings of 
MEP latency influenced by age [13]. In our study, we also 
could not determine age as an influencing factor, which 
might be caused by our cohort’s age distribution with 
mostly middle-aged patients (Table 1).
AED intake
In the present study, AED intake was identified as a com-
mon factor underlying MEP mu latency variability in all 
three of the analyzed muscles (APB, ADM, and FCR). 
Table 2 Motor evoked potential (MEP) latency by mapped muscle and gender
This table shows the minimum (Min), first quartile (1st Qu.), median, third quartile (3rd Qu.), and maximum (Max) values for motor evoked potential (MEP) latencies by 
mapped muscle and gender (in ms). In the present study, the abductor pollicis brevis muscle (APB), abductor digiti minimi muscle (ADM), flexor carpi radialis muscle 
(FCR), biceps brachii muscle (BCS), tibialis anterior muscle (TA), and gastrocnemius muscle (GCN) were mapped
Gender Muscle Min 1st Qu. Median 3rd Qu. Max
Male APB 19.14 22.18 23.29 24.56 30.76
ADM 18.94 22.00 23.20 24.19 32.50
FCR 13.66 16.60 18.00 19.22 22.12
BCS 12.93 14.06 15.69 17.56 20.40
TA 28.81 31.27 31.83 32.47 34.90
GCN 28.35 31.11 32.99 35.22 38.27
Female APB 18.07 20.80 21.63 22.26 32.09
ADM 17.76 20.44 21.47 22.79 22.79
FCR 12.75 14.88 16.15 17.19 19.68
BCS 10.51 12.28 14.15 15.77 15.77
TA 24.10 28.00 29.68 31.59 34.09
GCN 28.09 30.04 30.66 32.53 39.50
Fig. 1 Boxplots showing non-normally distributed motor evoked potential (MEP) latencies for mapped muscles of both genders. In the present 
study, the abductor pollicis brevis muscle (APB), abductor digiti minimi muscle (ADM), flexor carpi radialis muscle (FCR), biceps brachii muscle (BCS), 
tibialis anterior muscle (TA), and gastrocnemius muscle (GCN) were mapped
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During analyses, no AED intake was compared against 
levetiracetam, other specified AEDs, unspecified AEDs, 
and unknown AED status (Table 1). In this context, MEP 
latency was predicted to be slightly higher for unspeci-
fied AED intake and lower for specified AEDs. No clear 
difference was observed for predictions of unknown AED 
status or levetiracetam, in addition to no AED intake 
(Table 3; Figs. 4, 5, 6).
In past studies, levetiracetam was described as a 
potentially beneficial alternative to conventional AEDs 
in patients with brain tumors, which is based on com-
paratively rare drug interactions and side effects [34, 
35]. Therefore, this drug is increasingly used in the neu-
rosurgical context, allowing formation of a subgroup 
large enough for statistically meaningful analysis in the 
present study (Table 1). This was not the case for other 
AEDs, thus only allowing categorization in other speci-
fied or unspecified AEDs. These two groups are inhomo-
geneous with low numbers of observations, which does 
not allow attribution of MEP latency variability to a sin-
gle drug. However, our study raises awareness that AED 
intake in general has to be considered regarding MEP 
latencies. More importantly, it is able to show that lev-
etiracetam intake does not predict higher or lower MEP 
latencies when compared to no AED intake, which has 
not been investigated previously. This finding indicates 
that, besides rare drug interactions and side effects, lev-
etiracetam seems to be a favorable drug when it comes to 
nTMS-based motor mapping because it is not associated 
with significant alteration in MEP latencies according to 
our regression analysis.
In this context, the distinct effects of levetiracetam on 
cortical excitability are not fully understood, which is 
reflected by a comparatively limited amount of studies 
that at least partially arrived at opposing results [36–38]. 
Whereas the excitability in healthy volunteers was not 
significantly changed after a single oral dose of leveti-
racetam in one of these studies, the other two approaches 
described statistically significant rMT increases due to 
levetiracetam delivery, suggesting a drug-dependent 
decrease of neuronal excitability [36–38]. Regarding its 
way of functioning, it is assumed that levetiracetam pri-
marily decreases potassium currents and increases the 
decay of calcium currents, which is expressed by excit-
ability changes in the context of levetiracetam intake 
[39, 40]. As revealed by the present study, levetiracetam 
intake does not seem to predict higher or lower MEP 
latencies when compared to no AED intake. Hence, 
changes in excitability might still be present within rMT 
values or MEP amplitudes, but interestingly, MEP latency 
does not seem to be significantly affected by this kind of 
drug intake.
Muscle‑specific factors underlying MEP latency variability
rMT for APB
Studies comparing stimulation at threshold level with 
supra-threshold stimulation of one hemisphere showed 
that an increase in stimulation intensity leads to a 
stronger response with increased MEP amplitudes and 
decreased MEP latencies [23, 32]. On the contrary, we 
observed that in APB only, higher rMT was associated 
with an increase of MEP mu latencies. Therefore, our 
results do not represent changes in MEP latency due to 
mere stimulation intensity increase, but rather identify 
the rMT as an APB-specific factor for MEP latency vari-
ability (Table 3; Figs. 4, 5, 6).
In healthy volunteers, higher threshold intensities are 
actually related to longer MEP latencies [19, 32]. Studies 
assumed that direct corticospinal tracts with faster con-
nections have the lowest thresholds, whereas higher rMT 
stimulates predominantly indirect or polysynaptic con-
nections and therefore leads to longer MEP latencies. A 
Fig. 2 Graphs showing motor evoked potential (MEP) latencies as a function of the distance from the brain. The abductor pollicis brevis muscle 
(APB), abductor digiti minimi muscle (ADM), flexor carpi radialis muscle (FCR), biceps brachii muscle (BCS), tibialis anterior muscle (TA), and gastroc-
nemius muscle (GCN) were mapped in the present study
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Fig. 3 Boxplots showing the distribution of ex-Gaussian measures (mu, sigma, and tau) by mapped gyrus and gender. Again, the results are shown 
separately for each mapped muscle (APB abductor pollicis brevis muscle, ADM abductor digiti minimi muscle, FCR flexor carpi radialis muscle, BCS 
biceps brachii muscle, TA tibialis anterior muscle, GCN gastrocnemius muscle), depending on gender
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study on stroke patients presented that in lesioned hemi-
spheres, compared to healthy hemispheres, there are 
longer MEP latencies and higher rMTs [41]. A study on 
brain tumor patients also showed that differences in rMT 
between healthy and impaired hemispheres in tumor 
patients indeed can be found, although not in all—or 
even most—patients [14]. In our cohort, we accordingly 
assume that the higher rMT is an indicator for impair-
ment of motor pathways, which leads to recruitment of 
indirect connections and therefore a prolonged MEP mu 
latency. Still, these results have to be considered carefully, 
as this effect was seen only for one of the three stimulated 
muscles (APB). Further studies with higher MEP counts 
for each muscle are necessary to support our current 
results regarding rMT, and they might reveal the reason 
why this factor was identified as muscle-specific rather 
than common.
Tumor side for ADM
Interhemispheric differences in neurophysiological 
parameters are a controversial subject in the literature. 
As an example, for rMT, there are studies reporting dif-
ferences between the RH and LH [42], studies reporting 
differences between DO and NDO hemispheres [43], and 
studies reporting no interhemispheric difference [18]. For 
MEP latency, there are many studies on healthy volun-
teers, which showed no correlation between hemispheres 
(LH vs. RH nor DO vs. NDO  hemispheres), especially 
not after correction of UE lengths [13, 18, 31, 32]. A study 
on patients with brain tumors confirmed these findings 
[14].
Considering our results, we observed that, for ADM 
only, MEP mu latencies were predicted to be longer in 
LHs with brain tumors than in RHs with brain tumors 
according to our multiple regression approach (Table 3; 
Figs. 4, 5, 6). Although one would assume this is due to 
the dominancy of the LH, we did not observe this effect 
in the analysis of DO versus NDO hemispheres. With 
regards to our patients’ characteristics, gender distribu-
tion is not likely to cause this effect either, as both groups 
are similar (Table 1).
One possible explanation for why the tumor side was 
an underlying factor of variability in MEP latency while 
the hemisphere dominancy was not, might be that in 
left-handed patients we assumed the RH to be the motor-
dominant hemisphere. Of course, this is very reductive, 
as there are different gradations of handedness instead of 
just-right- or just-left-handedness. Still, this effect might 
not be of importance, as only 8% of our patients in total 
were left-handed. In any case, this interpretation remains 
speculative, and further studies might aim to clarify the 
finding that tumor side is a relevant factor—a result that 
has not yet been described in previous investigations. 
Upcoming studies should also distinctly explore why the 
tumor side was revealed to be a muscle-specific but not 
common factor.
Tumor location for FCR
In patients with eloquent brain tumors, the lesion fre-
quently impairs the functional connectivity of the brain—
either directly due to interaction with the cortical area or 
the corticospinal tract or indirectly due to a mass effect 
or edema—and can result in a loss of motor function. The 
worst deficits are expected when the primary motor cor-
tex is impaired directly by the tumor. This is in accord-
ance with our cohort, as patients with RO tumors tend 
to suffer from motor deficits most often compared to the 
other groups (motor deficit: RO 37%, FR 17%, PA 21%, 
PoG 35%, TE 20%).
We did not identify motor deficit as a significant pre-
dictor for MEP mu latency, but for FCR, MEP mu latency 
in patients with a tumor located in RO or TE regions was 
predicted to be longer than in those with tumors in PoG 
or FR areas, whereas MEP mu latencies of PA tumors 
ranged in the middle (Table 3; Figs. 4, 5, 6). It seems logi-
cal that tumors located in RO areas, other than in any 
other location, induce the largest changes in functional 
representation as they are situated directly within the pri-
mary motor cortex. We are currently aware of only one 
study researching the variability of MEP latency in brain 
tumor patients, which did not show any major differ-
ence in MEP latency between the healthy and impaired 
hemisphere [14]. Yet, there is a study on stroke patients 
showing longer MEP latencies after TMS of affected 
hemispheres when compared to healthy hemispheres 
[41]. As for the TE tumor group, these patients tended 
to have the largest tumor volumes out of all groups, and 
we assume the longer MEP mu latencies are due to the 
Table 3 Significant predictor variables for  motor evoked 
potential (MEP) latency by mapped muscle
This table shows the predictor variables for MEP latencies that were statistically 
significant. In this context, common factors (gender and antiepileptics = AED) 
and muscle-specific factors (resting motor threshold = rMT, tumor side, tumor 
location) were revealed for abductor pollicis brevis muscle (APB), abductor digiti 
minimi muscle (ADM), and flexor carpi radialis muscle (FCR)
Muscle Predictors p
APB MEP latency (mu) (n = 197) Plus gender <0.001
Plus AED 0.012
Plus rMT 0.008
ADM MEP latency (mu) (n = 192) Plus gender 0.001
Plus AED 0.016
Plus tumor side 0.009
FCR MEP latency (mu) (n = 157) Plus gender <0.001
Plus AED 0.012
Plus tumor location 0.016
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subcortical spatial relation of tumor tissue to the corti-
cospinal tract and its compression [19].
It is of interest to discern whether these variables are 
directly associated with motor deficits of contralateral 
limbs or with mere changes in structural anatomy. The 
analysis of our cohort indicates the latter, but as these 
results were significant only for one of three analyzed 
muscles, further studies with higher MEP counts and dif-
ferent muscles (not solely UE muscles) are crucial.
Limitations
Despite that this study successfully identified significant 
common and muscle-specific predictors regarding MEP 
latency variability in nTMS-based motor mapping, some 
important shortcomings have to be reported. In this 
context, we only investigated the lesioned hemisphere, 
which makes comparisons between diseased and healthy 
hemispheres within the same patients impossible. How-
ever, such interhemispheric comparisons might be useful 
for assessing the functional status of the motor system 
with later implications for risk stratification, as demon-
strated in a previous study [14]. Although the lack of data 
analysis among healthy hemispheres in the present study 
should not restrict the significance of our data per se, 
such interhemispheric comparison might be considered 
during upcoming investigations.
Furthermore, our multiple regression analysis solely 
included a set of UE muscles (APB, ADM, FCR), whereas 
LE muscles were only initially mapped and recorded 
by EMG (TA, GCN) but not taken into account during 
Fig. 4 This figure plots the means and confidence intervals (CIs) of the factors that were revealed to be statistically significant regarding motor 
evoked potential (MEP) latency variability for the abductor pollicis brevis muscle (APB). In this context, gender (M male, F female), antiepileptics 
(AEDs: NA no AED, L levetiracetam, SA other specified AEDs, NK AED status not known, UA unspecified AEDs), and resting motor threshold (rMT, in % 
of the system’s maximum output) are depicted
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regression analysis. This was due to the fact that the map-
ping of these LE muscles unfortunately did not lead to 
numbers of observations needed to run this kind of sta-
tistical analysis [26–30], thus restricting our findings to 
the UE muscles and leaving space for similar approaches 
in LE muscles, which would require higher MEP counts.
Importantly, body height was not considered as an iso-
lated factor fed into multiple regression analysis. How-
ever, since this factor is most likely related to gender, 
we can certainly assume that it contributed to the iden-
tified variability in gender that was revealed as a com-
mon predictor variable. In this context, previous studies 
have repeatedly reported that MEPs recorded from UE 
muscles are generally correlated to body height [13, 
31, 33]. Hence, this factor should be included in future 
approaches on MEP latency variability among brain 
tumor patients.
Furthermore, we only used rMTs derived from APB 
stimulation for mapping of motor areas. This approach 
allows for differentiation of findings that are specific to 
single muscles (muscle-specific factors) and findings 
that are observed in all muscles together (common fac-
tors), but only against the background of mapping with 
a muscle-specific, APB-derived rMT. Thus, our findings 
are primarily relevant for current mapping procedures 
that use the APB for rMT determination, which is, how-
ever, in line with most previous neurosurgical mapping 
studies [5, 10, 20–22]. It has to be confirmed whether 
Fig. 5 This figure plots the means and confidence intervals (CIs) of the factors that were revealed to be statistically significant regarding motor 
evoked potential (MEP) latency variability for the abductor digiti minimi muscle (ADM). In this context, gender (M male, F female), antiepileptics 
(AEDs: NA no AED, L levetiracetam, SA other specified AEDs, NK AED status not known, UA unspecified AEDs), and tumor side (LH left hemisphere, RH 
right hemisphere) are depicted
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comparable results are also present for mapping with 
rMTs derived from other muscles (e.g., ADM or FCR).
Clinical implications and significance
This is one of the first studies that uses nTMS to system-
atically explore MEP latency distributions and, in a sec-
ond step, identifies clinical factors that may underlie MEP 
latency variability. In this context, there is only a limited 
amount of literature on MEP characteristics derived from 
nTMS, which primarily reports results derived from 
healthy subjects [13, 19]. To the best of our knowledge, 
there is only one comparable approach among neuro-
surgical patients available while the use of this technique 
for neurosurgical mapping strongly increases [14]. Thus, 
more data on the matter seems to be mandatory for 
further successful and reliable application of nTMS in 
neurosurgery. Consequently, the specific need for data 
on MEP characteristics among neurosurgical patients has 
already been pointed out in one of the previous investiga-
tions in healthy volunteers [19]. Therefore, the results of 
the present study add knowledge to the limited amount 
of data on the matter.
While there is a comparatively large body of literature 
on MEP amplitudes and latency variability and influenc-
ing factors derived from stimulation with non-navigated 
TMS systems [11, 12, 15–17], only a few studies thus far 
have used nTMS [13, 14, 19]. This situation is of high 
importance since it is known that only slight variations 
in coil placement and angulation can lead to different 
responses [18]. Thus, although previous non-navigated 
TMS approaches heavily contributed to the knowl-
edge about MEP characteristics, we can assume that 
Fig. 6 This figure plots the means and confidence intervals (CIs) of the factors that were revealed to be statistically significant regarding motor 
evoked potential (MEP) latency variability for the flexor carpi radialis muscle (FCR). In this context, gender (M male, F female), antiepileptics (AEDs: 
NA no AED, L levetiracetam, SA other specified AEDs, NK AED status not known, UA unspecified AEDs), and tumor location (RO Rolandic, FR frontal, 
PA parietal, PoG postcentral gyrus, TE temporal) are depicted
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non-navigated stimulation might have been confounded 
by non-optimal coil adjustments, which can limit the 
validity and reproducibility of such data. In this context, 
the spatial extent of motor maps, MEP amplitudes at cer-
tain mapping points, and MEP latencies might be insuf-
ficient due to non-optimal coil placement; a factor that 
can be controlled during nTMS [3]. While data on the 
extent of nTMS-based motor maps were not the topic of 
the present study and have already been published [20], 
an update on MEP characteristics and influencing factors 
by the use of nTMS seemed to be necessary in the neuro-
surgical context.
Regarding influencing factors, at least some of the 
parameters investigated are specific to brain tumors, 
which make their assessment impossible in nTMS-based 
studies among healthy volunteers. In this context, data 
on tumor-specific factors have solely been investigated 
in one study so far [14]. Whereas this study predomi-
nantly revealed negative results in the sense that no fac-
tors except gender were identified as underlying variables 
of MEP latency variability [14], the present approach 
revealed more common and muscle-specific factors as 
significant while considering a larger set of predefined 
variables.
Nevertheless, the present study only revealed two sig-
nificant common factors and three muscle-specific fac-
tors for MEP latency variability out of a predefined set 
consisting of 14 clinical factors. This can be regarded as 
beneficial regarding neurosurgical motor mapping since 
it demonstrates that only a few variables interfere with 
MEP latency and, therefore, should be documented and 
controlled, if possible. However, it is interesting that at 
least some significant factors have been revealed since 
MEP latencies have principally shown to be among 
the most stable parameters during TMS applications, 
whereas MEP amplitudes, for instance, can considerably 
vary from stimulus to stimulus due to rather unspecific 
reasons [11–14].
Despite that nTMS-based mapping in neurosurgery is 
primarily used for preoperative planning, its application 
is increasingly expanded to delineation of plastic reshap-
ing in the context of brain tumors. Such plastic changes 
can occur to different extents, but they have repeatedly 
been demonstrated by nTMS and intraoperative stimula-
tion [44–47]. Delineation of plastic changes commonly 
requires follow-up mappings to compare the spatial 
characteristics of the motor maps. However, some of the 
significant factors identified in the present study may 
change during the interval between initial and follow-up 
mapping (e.g., AED doses), and because they have shown 
to underlie MEP latency variability, they should be care-
fully documented and considered to prevent confound-
ing of results when MEP latency is, among others, used 
as a parameter to distinguish between motor-positive 
and motor-negative stimulation spots. Such confounding 
could be due to different mapping hotspots and numbers 
of motor-positive stimulation points between initial and 
follow-up mapping, which might be wrongly attributed 
to plasticity while being rather related to different motor 
maps due to changed clinical factors. Consequently, the 
factors identified in the present study should facilitate 
better control and understanding of nTMS mapping 
parameters in neurosurgery.
In addition to distinguishing between motor-positive 
and motor-negative spots, neurophysiological nTMS 
criteria, such as MEP latency, might be used to assess 
the functional status of the motor system in the course 
of a disease like brain tumors, for instance. While first 
approaches have been made in the context of neurosur-
gery by interhemispheric comparison of such values [14], 
they cannot yet be regarded as routine, and more studies 
are needed to clarify applicability. The present study can 
be seen as another step that might lead to individual risk 
stratification based on nTMS characteristics in the long 
run.
Furthermore, information regarding subcortical tracts 
can be provided by nTMS when combined with diffusion 
tensor imaging fiber tracking (DTI FT), as demonstrated 
in recent studies [48–51]. In this context, MEP latency 
maps could be used to refine the nTMS-based DTI FT 
approach in the sense that stimulation spots with the 
shortest MEP latencies could be used as seed regions to 
improve motor pathway tracking [51]. In contrast, stim-
ulation points with rather long MEP latencies might be 
indicative of pathways under stress in the context of tract 
compressions due to space-occupying brain lesions, as 
suggested in a recent approach [19]. Again, knowledge 
about the factors contributing to MEP latency variability 
is essential for accurate mapping and DTI FT, and it helps 
to understand underlying neurophysiologic mechanisms. 
To increasingly exploit these neurophysiological nTMS 
characteristics in patients with brain tumors that could 
be supplementary to preoperative motor mapping, fur-
ther studies are needed.
Conclusions
Based on a large cohort of neurosurgical patients, this 
study provides data on MEP latency distributions and 
a wide range of clinical factors that may underlie MEP 
latency variability in nTMS-based motor mapping of 
brain tumor patients. We were able to reveal significant, 
common factors (gender, associated with height, and 
AED) as well as muscle-specific factors (rMT, tumor side, 
tumor location) for MEP latency variability. Whereas 
the common factors can easily be discussed against the 
background of previous research (mainly acquired with 
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non-navigated stimulation), some of the findings on 
significant muscle-specific factors cannot be distinctly 
clarified by the data of the present  or previous studies. 
Nevertheless, the results of our approach might further 
refine nTMS-based motor mapping, and they should be 
taken as a basis for specific research on single, significant 
muscle-specific factors in the future.
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